Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly … Read more
Fennec Pharmaceuticals Inc (FENC) - Total Liabilities
Latest total liabilities as of September 2025: $53.70 Million USD
Based on the latest financial reports, Fennec Pharmaceuticals Inc (FENC) has total liabilities worth $53.70 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Fennec Pharmaceuticals Inc - Total Liabilities Trend (1999–2024)
This chart illustrates how Fennec Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Fennec Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Fennec Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shenzhen RoadRover Technology Co Ltd
SHE:002813
|
China | CN¥257.39 Million |
|
Dune Acquisition Corporation II Units
NASDAQ:IPODU
|
USA | $5.83 Million |
|
Prince Pipes And Fittings Limited
NSE:PRINCEPIPE
|
India | ₹6.34 Billion |
|
Beijing Navigation Control Technology Co. Ltd.
SHG:688282
|
China | CN¥227.23 Million |
|
Ningbo Peace Bird Fashion
SHG:603877
|
China | CN¥3.29 Billion |
|
Vivozon Healthcare Inc
KQ:082800
|
Korea | ₩82.73 Billion |
|
Southeast Cement Co Ltd
TW:1110
|
Taiwan | NT$3.10 Billion |
|
Seetel New Energy Co., Ltd.
TW:7740
|
Taiwan | NT$8.10 Billion |
Liability Composition Analysis (1999–2024)
This chart breaks down Fennec Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -11.97 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Fennec Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Fennec Pharmaceuticals Inc (1999–2024)
The table below shows the annual total liabilities of Fennec Pharmaceuticals Inc from 1999 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $50.82 Million | +32.04% |
| 2023-12-31 | $38.49 Million | +30.43% |
| 2022-12-31 | $29.51 Million | +344.26% |
| 2021-12-31 | $6.64 Million | +183.00% |
| 2020-12-31 | $2.35 Million | +3.35% |
| 2019-12-31 | $2.27 Million | +38.73% |
| 2018-12-31 | $1.64 Million | -0.43% |
| 2017-12-31 | $1.64 Million | +308.96% |
| 2016-12-31 | $402.00K | -14.65% |
| 2015-12-31 | $471.00K | -73.22% |
| 2014-12-31 | $1.76 Million | -45.15% |
| 2013-12-31 | $3.21 Million | -56.20% |
| 2012-12-31 | $7.32 Million | +33.83% |
| 2011-12-31 | $5.47 Million | -49.89% |
| 2010-12-31 | $10.92 Million | +2456.67% |
| 2009-12-31 | $427.00K | -85.80% |
| 2008-12-31 | $3.01 Million | -1.76% |
| 2007-12-31 | $3.06 Million | -65.99% |
| 2006-12-31 | $9.00 Million | +7.28% |
| 2005-12-31 | $8.39 Million | -3.94% |
| 2003-12-31 | $8.73 Million | -15.63% |
| 2002-12-31 | $10.35 Million | +1306.04% |
| 2001-12-31 | $736.04K | +15.84% |
| 2000-12-31 | $635.41K | +6.53% |
| 1999-12-31 | $596.46K | -- |